Condition
Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Rigosertib Oral Capsules Rigosertib Intravenous
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Research Network
Common Treatments
- Rigosertib Oral Capsules Rigosertib Intravenous1
- Rigosertib Sodium1
Active Sponsors
- Prof. Johann Bauer1
- Eb Haus Austria Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH1
Top Investigators
Department of Dermatology, Paracelsus Medical University, Salzburger Landeskliniken
Related Conditions
- Squamous Cell Carcinoma1
- Epidermolysis Bullosa Dystrophica1